Nilogen Oncosystems

Executive Summary

Nilogen Oncosystems is a Tampa-based biotechnology company founded in 2015 that specializes in developing advanced 3D cancer models derived from fresh human tumor tissue. The company's proprietary platform aims to improve the success rate of oncology drug development by providing clinically relevant ex vivo testing environments. By preserving the native tumor microenvironment, Nilogen's models enable more accurate prediction of drug efficacy and toxicity, potentially reducing the high failure rates in clinical trials. The technology addresses a critical gap in oncology research, where traditional 2D cell cultures and animal models often fail to replicate human tumor biology. With a focus on both oncology and diagnostics, Nilogen serves pharmaceutical and biotech partners seeking to de-risk their drug development pipelines. The company operates as a private entity and has not disclosed funding or valuation details, but its approach aligns with the growing industry demand for more predictive preclinical tools.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major pharmaceutical company60% success
• Q1 2027Publication of validation data in a peer-reviewed journal70% success
• Q3 2026Launch of a new service line for immuno-oncology drug testing50% success